Nada Hindiyeh
Neurology · San Francisco, CANPI 1831320720
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Lilly USA, LLC at 39.1% of the total. Reporting peaked in 2019 at $112,916 and has fallen 83.6% since, to $18,491 in 2025. Among neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 292 payments — averaging $918.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$105K
- Lundbeck LLC$68K
- Impel Pharmaceuticals Inc.$37K
- Eli Lilly$16K
- Axsome Therapeutics, Inc.$13K
- Amgen$11K
- plus $18K from 7 others
Across 275 payments — averaging $1507.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Innovation$221K
- AbbVie$92K
- H. Lundbeck A S$35K
- Novartis$23K
- Eli Lilly$18K
- Pfizer$15K
- plus $11K from 2 others
What the payments were for
- Consulting fees$140,25752%
- Speaking & faculty fees$67,83725%
- Travel & lodging$52,71720%
- Food & beverage$6,5882%
- Education$7940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 129 | $104,843 |
| Lundbeck LLC | 33 | $68,025 |
| Impel Pharmaceuticals Inc. | 26 | $37,496 |
| Eli Lilly | 43 | $15,696 |
| Axsome Therapeutics, Inc. | 5 | $13,342 |
| Amgen | 12 | $10,867 |
| H. Lundbeck A S | 4 | $5,649 |
| Novartis | 12 | $4,805 |
| AbbVie(2 entities) | 15 | $3,399 |
| Pfizer | 7 | $3,386 |
| Ipsen Innovation | 4 | $597 |
| Ipsen Biopharmaceuticals, Inc | 1 | $66 |
| Pharming Healthcare, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$268,193 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 12 | $22,599 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $3,386 | $22,59912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.
Other neurology in San Francisco
- S Claiborne JohnstonSan Francisco$576K
- Armen MoughamianSan Francisco$554K
- Scott ZamvilSan Francisco$447K
- Bruce CreeSan Francisco$412K
- Kenneth LaxerSan Francisco$379K
- Jonathan KatzSan Francisco$294K
- Douglas GoodinSan Francisco$227K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.